AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

Go back to AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
AbbVie (NYSE: ABBV) Delayed: 284.80 -4.28 (1.48%)
Previous Close $289.08    52 Week High $68.12 
Open $287.63    52 Week Low $50.71 
Day High $289.00    P/E 61.78 
Day Low $282.15    EPS $4.61 
Volume 4,394,198